Exero Medical Appoints Prominent Gastrointestinal Expert Professor Charles Knowles to its Scientific Advisory Board

Exero Medical, developer of a biodegradable wireless sensor for early detection of anastomotic leaks (AL) following GI surgery, today announced the appointment of Charles Knowles, Professor of Surgery at Queen Mary University of London and Consultant Colorectal Surgeon at Barts Health NHS Trust, to its scientific advisory board.

“We are excited to welcome Professor Charles Knowles, whose clinical expertise and deep knowledge of the gastrointestinal field brings immediate value to Exero Medical, and will be instrumental in navigating both clinical trials and clinical implementation of our AL detection technology,” said Erez Shor, PhD, CEO of Exero Medical. “Professor Knowles provides us with an axis between the operation and functionality of our leak detection system and its clinical application. His expert input will be vital in the development of our technology, which will result in better, safer care of GI surgery patients.”

Professor Knowles has been a major contributor to the field of gastrointestinal research for over 25 years. Professor Knowles is Deputy Director of the Blizard Institute and Honorary Professor of Experimental Therapeutics at UCL. He is Chair of several research committees including the European Society of Coloproctology. Professor Knowles has authored over 190 peer reviewed publications as well as contributed several book chapters to major international colorectal and general surgical texts.

“AL has a 6-10% occurrence rate post-operation in lower GI procedures and can lead to life threatening complications, with substantial risk of mortality,” said Professor Knowles. “I look forward to working closely with the Exero Medical team, whose technology is novel to this field, to address this widespread issue and help alert physicians to post-operative AL early on, allowing for timely medical intervention and improved patient outcomes.”

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”